Previous 10 | Next 10 |
2023-07-31 18:17:01 ET Summary Adlai Nortye Ltd. has filed to raise $115 million in a U.S. IPO, although the final figure may differ. The firm is a clinical stage biopharma developing immunotherapy treatments for solid tumor cancer conditions. Adlai Nortye is in Phase 3 trials...
2023-07-30 09:05:25 ET Summary Alnylam partnered Roche to develop and commercialize zilebesiran for the treatment of hypertension. Alnylam's share price has not benefited as the announcement was followed by the company revealing a very long development timeline for the candidate. ...
2023-07-29 21:50:55 ET Summary The launch of Briumvi is off to a solid start, but the stock pulled back recently and fell more after Roche reported positive phase 3 results of subcutaneously administered Ocrevus. The improved convenience of SC Ocrevus is an overblown risk factor, ...
2023-07-28 14:33:13 ET As July gives way to August, the upcoming week is jam-packed with earnings reports from some of the biggest companies in the world. The highlighted companies include Apple ( NASDAQ: AAPL ), Amazon ( NASDAQ: AMZN ), Advanced Micro Devices...
2023-07-27 09:08:44 ET Going into AbbVie's ( NYSE: ABBV ) latest quarterly results, much investor attention focused on sales of its blockbuster autoimmune conditions treatment Humira , which is now facing the first generic competition in its history. After reigning as the world'...
2023-07-26 23:18:28 ET Summary Intellia is a pipeline-stage firm, leveraging gene-editing technology to develop therapies for rare diseases. NTLA is on track toward key data and regulatory catalysts. Early clinical data in HAE and ATTR have provided solid validation for Intellia's...
2023-07-26 10:01:40 ET One thing that can often drive up a stock's value is an increase in guidance. And two companies that recently boosted their projections for the year are Novartis (NYSE: NVS) and PepsiCo (NASDAQ: PEP) . Both businesses are showing strong growth despite ...
2023-07-24 19:15:20 ET Summary Curis, a microcap biotech company, is focusing on the development of cancer drugs, currently supporting six drug trials with a burn rate of over $30 million per year. Despite a recent direct offering adding $15.1 million to its balance sheet and a lo...
2023-07-23 08:30:00 ET For a dividend investor, generating enough income to become and stay financially independent (higher passive income than expenses) comes down in large part to the longevity of the businesses in an investment portfolio. Here's what I mean: When you invest your mone...
2023-07-23 05:45:00 ET Summary Novartis has signed a $1 billion deal to acquire DTx Pharma - DTx Pharma shareholders will receive $500 million upfront and up to $500 million in milestones. Sichuan Kelun-Biotech completed a $174 million IPO on the Hong Kong Exchange, valuing the co...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...